Search
Search Results
-
A case report and literature review of IgA nephropathy presenting as nephrotic syndrome in polycythemia vera
A 66-year-old non-smoker presented with a 2-week history of new-onset pedal oedema and gross haematuria. On evaluation, he was found to be...
-
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The...
-
Inferior Survival Among Polycythemia Vera Patients Exhibiting Body Mass Index Reduction
The prognostic significance and the predictive factors for weight loss are not entirely elucidated for Polycythemia Vera (PV). In this single-center...
-
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
Hematological control, incidence of complications, and need for cytoreduction were studied in 453 patients with low-risk polycythemia vera (PV)...
-
Ischemic enteritis resulting from polycythemia vera
Polycythemia vera is a chronic myeloproliferative disorder characterized by clonal proliferation of bone marrow progenitors. We report a case of...
-
Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices
Polycythemia vera (PV) is a burdensome, chronic myeloproliferative neoplasm characterized by activating mutations in Janus kinase 2, erythrocytosis,...
-
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b
Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by clonal erythrocytosis. A phase 2 study...
-
Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century
Polycythemia vera (PV) is a myeloproliferative tumor with low incidence and complex symptoms, affecting patients' quality of life and shortening...
-
High platelet-to-lymphocyte ratio may differentiate polycythemia vera from secondary polycythemia
Discriminating polycythemia vera (PV) from secondary polycythemia (SP) is crucial due to the inherent risk of thrombosis in PV and different...
-
Blocking the CD47-SIRPα interaction reverses the disease phenotype in a polycythemia vera mouse model
Polycythemia vera (PV) is a hematopoietic stem cell neoplasm driven by somatic mutations in JAK2 , leading to increased red blood cell (RBC)...
-
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin...
-
Honeycomb-like structure (HLS) in the left anterior-descending coronary artery—recanalized thrombus demonstrated by intravascular ultrasound (IVUS) in a patient with polycythemia vera and thrombocythemia
A 71 year old male patient who experienced acute myocardial infarction (AMI) 4 years ago and had a history of polycythemia vera and thrombocythemia...
-
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension
Essential Thrombocythemia (ET) and Polycythemia Vera (PV) are chronic myeloproliferative neoplasms (MPNs) characterized by thrombotic and hemorrhagic...
-
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis
There are few prospective studies on patients with post-essential thrombocythemia myelofibrosis (PET-MF) and post-polycythemia vera myelofibrosis...
-
Intermittent retinal artery occlusions as the first clinical manifestation of polycythemia vera: a case report
BackgroundPolycythemia vera (PV) is a myeloproliferative neoplasm with increased hemoglobin, hematocrit, platelet count and leukocytosis, resulting...
-
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes
Ropeginterferon-alfa2b (ropegIFNα2b) is a long-acting IFN formulation with broad FDA/EMA approval as a therapy of polycythemia vera (PV) with no...
-
Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
Janus kinase 2 ( JAK2 ) V617F mutation is present in most patients with polycythemia vera (PV). One persistently puzzling aspect unresolved is the...
-
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events (TEs). Predisposing factors have been...
-
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b (Ropeg) 100 µg every 2 weeks for 2 years was more effective...
